Table 1.

Association between EmiR expression at Ext1 and clinicopathological characteristics in LBC patients

			Ext1
			EmiR-21		EmiR-222		EmiR-221		EmiR-105		EmiR-155
		n	Median	p value	Median	p value	Median	p value	Median	p value	Median	p value
Age (years)	< 50	27	1.518	0.983	1.506	0.966	1.161	0.667	11.199	0.897	1.901	0.302
	≥ 50	20	1.671		1.592		1.375		8.362		3.247
Menopause	Pre	30	1.579	0.330	1.585	0.658	1.399	0.232	9.474	0.947	1.904	0.250
	Post	17	1.424		1.424		1.088		8.597		3.370
T	T1–T2	27	1.265	0.039*	1.506	0.813	1.173	0.780	3.851	0.067	1.906	0.093
	T3–T4	20	1.787		1.556		1.379		22.184		4.073
N	0	20	1.443	1.000	1.315	0.342	1.197	0.733	8.362	0.846	2.436	0.770
	1–3	23	1.543		1.584		1.088		30.239		3.019
Estrogen receptor	Negative	13	1.615	0.812	2.992	0.161	1.221	0.812	49.757	0.140	2.776	0.981
	Positive	34	1.462		1.417		1.155		7.072		2.892
Progesterone receptor	Negative	17	1.615	0.773	2.992	0.018*	1.597	0.465	49.757	0.116	2.776	0.947
	Positive	30	1.403		1.271		1.064		7.072		2.778
HER2	Negative	36	1.531	0.466	1.465	0.880	1.149	0.563	8.362	0.744	3.117	0.421
	Positive	11	1.265		2.019		1.596		14.130		1.055
KI67	< 20%	8	1.157	0.458	0.850	0.050	1.279	0.573	3.380	0.103	2.219	0.373
	≥ 20	37	1.518		1.584		1.161		14.130		3.019
Perou’s classification	Basal-like	8	1.566	0.976	3.179	0.037*	1.191	0.986	39.998	0.306	4.127	0.495
	Luminal A	7	1.543		0.803		1.656		3.389		1.901
	Luminal B	27	1.424		1.513		1.139		7.750		3.215
	HER2neu	5	1.960		2.094		1.597		60.097		1.055

Wilcoxon signed-rank test and Kruskal-Wallis test were used. Abbreviations: CTCs circulating tumor cells, Ext1 basal extraction, Ext2 extraction during neoadjuvant treatment, T tumor size, N lymph node status. *p > 0.05